These findings suggest that SM-164 has at least 100-fold greater efficacy than BV6 or AT-406 to degrade cIAP1 and cIAP2, paralleling its greater potency to kill cancer cells in the presence of TNFα (Fig. 4B). This evidence concerns the gene BIRC3 and cancer.